Business decision based on lack of enrollment

The purpose of this study is to evaluate the incidence and management of infusion reactions with Golimumab intravenous infusion.

This is a prospective, observational, non-interventional (no treatment given during course of the study) multi-center (when more than one hospital or medical school team work on a medical research study), study that will enroll participants with rheumatoid arthritis (RA) in Canada. Only data available from source documentation will be collected. The participation in this study will not impact on the standard of care of the participant or any benefits to which they are otherwise entitled. All aspects of treatment decisions and clinical management of participants will be in accordance with clinical practice and at the discretion of the health care provider. Participants' safety will be monitored throughout the study.

Inclusion Criteria:

• Participants must have a confirmed diagnosis of rheumatoid arthritis
• Participants must have provided a written consent for data collection by signing an informed consent form indicating that he/she understand the purpose and procedures for data collection and are willing to participate in the study
• Participants are golimumab-naive (never have used golimumab both SC and IV formulations)
• Participants are prescribed golimumab intravenous by an appropriate physician as per the Canadian Product Monograph

Exclusion criteria:

• Participant who has been treated with golimumab in the past
• Participant has been diagnosed with psoriatic arthritis or ankylosing spondylitis
• Participant has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study or first data collection time point
• Participant is currently enrolled in an interventional study

Canadian participants with rheumatoid arthritis (RA), who have been prescribed intravenous golimumab prior to, and independently of, study enrollment.